Häussler B, Gothe H, Göl D, Glaeske G, Pientka L, Felsenberg D
IGES Institute for Healthcare and Social Research Ltd., Wichmannstrasse 5, 10787 Berlin, Germany.
Osteoporos Int. 2007 Jan;18(1):77-84. doi: 10.1007/s00198-006-0206-y. Epub 2006 Sep 19.
In Germany, accurate data on the prevalence and treatment of osteoporosis, as well as the cost of this illness, are not available. The aim of this study is to give a valid estimation of these items for the year 2003.
Routine data from a German sickness fund covering 1.5 million beneficiaries and billing data for outpatient visits were used to obtain estimates of prevalence for osteoporosis. Claims data for patients with osteoporosis (M80, M81) or an osteoporosis-related fracture diagnosis (S22, S32, S42, S52, S72, S82) or treatment with anti-osteoporosis drugs were examined. Costs were calculated from the perspective of the German health insurance system and the German nursing care insurance system, respectively. Only direct costs of osteoporosis were considered.
In 2003, 7.8 million Germans (6.5 million women) were affected by osteoporosis. Of them, 4.3% experienced at least one clinical fracture. Only 21.7% were treated with an anti-osteoporosis drug. The total direct costs attributable to osteoporosis amounted to euros 5.4 billion.
This study confirms that osteoporosis is underdiagnosed, undertreated and imposes a considerable economic burden on the health system in Germany. Effective strategies for the prevention and management of this disease are needed.
在德国，缺乏关于骨质疏松症患病率、治疗情况以及该疾病成本的准确数据。本研究的目的是对2003年的这些数据进行有效估算。
利用一家德国疾病基金覆盖150万受益人的常规数据以及门诊就诊的计费数据来获取骨质疏松症患病率的估算值。对患有骨质疏松症（M80、M81）或骨质疏松症相关骨折诊断（S22、S32、S42、S52、S72、S82）或接受抗骨质疏松药物治疗的患者的理赔数据进行了检查。成本分别从德国医疗保险系统和德国护理保险系统的角度进行计算。仅考虑骨质疏松症的直接成本。
2003年，780万德国人（650万女性）受骨质疏松症影响。其中，4.3%经历了至少一次临床骨折。只有21.7%接受了抗骨质疏松药物治疗。归因于骨质疏松症的直接成本总计达54亿欧元。
本研究证实，骨质疏松症在德国存在诊断不足、治疗不足的情况，并且给卫生系统带来了相当大的经济负担。需要有效的疾病预防和管理策略。
